Novocure’s Optune Lua® Gets CE Mark for mNSCLC Treatment Novocure (NASDAQ: NVCR) has announced that its Optune Lua® device has received the CE Mark (Conformité Européenne) for treating adult patients with metastatic non-small cell lung cancer (mNSCLC) who are undergoing…
GI Alliance and Iterative Health Partner to Boost GI Clinical Research GI Alliance (GIA), a leading physician-led gastroenterology network and a Cardinal Health company, has announced a strategic partnership with Iterative Health, a healthcare technology and services firm that specializes…
Ivonescimab + Chemo Outperforms PD-1 Combo in 1L Squamous NSCLC in Akeso’s HARMONi-6 Study Summit Therapeutics Inc. (NASDAQ: SMMT) has announced that Akeso, Inc. (HKEX: 9926.HK) has successfully met the primary endpoint of progression-free survival (PFS) in its Phase III…
Calyxo Marks One Year of 2nd-Gen CVAC System at AUA 2025 Calyxo, Inc., a medical device company revolutionizing kidney stone treatment, is marking the one-year anniversary of its second-generation CVAC System at the American Urological Association (AUA) 2025 Annual Meeting,…
Augurex Gains UKCA Approval for SPINEstat™ Axial Spondyloarthritis Test Augurex Life Sciences, a pioneer in autoimmune biomarker diagnostics, announced that its SPINEstat™ blood test has received UK Conformity Assessed (UKCA) marking from the Medicines and Healthcare products Regulatory Agency (MHRA).…
Epicrispr & Springbok Partner on AI Muscle Analysis for First FSHD Human Study Epicrispr Biotechnologies, a company dedicated to developing curative gene-modulating therapies, has announced a strategic partnership with Springbok Analytics. The collaboration will integrate advanced AI-based muscle MRI imaging…
Sun Nuclear Achieves EU MDR Class IIb CE Certification for Key QA Solutions Sun Nuclear, a Mirion Medical company, announced that its SunCHECK® software and key radiation therapy quality assurance (QA) devices have successfully completed the transition to CE Class…
Innate Pharma Reclaims CD123 ANKET® Rights, Sanofi Plans Strategic Investment Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA), a clinical-stage biotechnology company specializing in immunotherapies for cancer, has announced significant developments in its collaboration with Sanofi. The companies have mutually…
Ironwood to Present Data on New Diagnosis Code Use in SBS Patients at DDW 2025 Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company dedicated to developing and commercializing transformative therapies for gastrointestinal (GI) and rare diseases, announced that it will…
Bristol Myers Shares Phase 3 Results for Cobenfy in Schizophrenia Treatment Bristol Myers Squibb (NYSE: BMY) has announced the topline results from the Phase 3 ARISE trial, assessing the efficacy and safety of Cobenfy™ (xanomeline and trospium chloride) as an…